Niagen Bioscience, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences, Inc.' 's first quarter of 2025 earnings conference call. My name is Kayla, and I will be the conference operator today. At this time, all participants are in a listen-only mode, and as a reminder, this conference call is being recorded. This afternoon, Niagen Biosciences issued a news release announcing the company's financial results for the first quarter of 2025. If you have not reviewed this information, both are available within the Investor Relations section of Niagen Bioscience's website at www.niagensbioscience.com. I would now like to turn the conference call over to Wesley Yu, Vice President of Finance. Please go ahead, Mr. Yu.

Thank you. Good afternoon, and welcome to Niagen Bioscience's first quarter of 2025 conference call. With us today are Nijen Biosciences Chief Executive Officer Rob Fried, Chief Financial Officer Ozan Tamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Hsiao. Dr. Hsiao will join the call for Q&A. Today's conference call may include forward-looking statements, including statements related to the company's research and development and clinical trial plans and the timing and results of such trials. The timing of future regulatory filings, the expansion of the sale of nitrogen products and ingredients in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interests, and business prospects and opportunities, as well as anticipated results of operations. Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause nitrogen bioscience's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in NIGEN Biosciences quarterly report on Form 10-Q, most recently filed with the SEC, including results of operations, financial conditions, cash flows, as well as global market and economic conditions on our business. Please note that the company assumes no obligation to update any forward-looking statements after debate of this conference call to conform with the forward-looking statements, actual results, or to changes in its expectations. In addition, certain financial information presented in this call references non-GAAP financial measures. The company's earnings presentations and earnings press release, which were issued this afternoon, are available on the company's website. Present reconciliations to the appropriate GAAP measures. Finally, this conference call is being recorded via webcast. The webcast will be available at the Investors Relations section of our website at www.nihanbioscience.com. With that, it's now my pleasure to turn the call over to our Chief Executive Officer, Rob Freed.

Thank you, Wesley, and good afternoon, everyone, and thank you for joining us on our first ever investor call as Niagen Bioscience, formerly known as Chromadex. I am pleased to announce that we had an excellent start to 2025. In the first quarter, we delivered $30.5 million in revenue, a 38% year-over-year increase, and we delivered net income of $5.1 million. We generated $7.9 million of cash from operations, and we ended the quarter with $55.6 million in cash and no debt. In this first quarter, our e-commerce continued to be a main driver of our top-line growth, with net sales of $16.8 million a 31% increase year-over-year. Our food-grade and pharmaceutical-grade Niagen ingredient business grew to $8 million, a 95% increase year-over-year. Our Niagen Plus product remains a key focus area for the company. Niagen Plus refers to intravenous and injection Niagen. This is available now at almost 600 clinics nationwide. In the last few months, we've partnered with clinics at different events and conferences, including the SoCal Wellness Summit, BioHackers World, to offer Niagen Plus to influencers and consumers. The feedback has been extremely positive, with many commenting on the much faster infusion time than NAD IV, with minimal side effects and many stating that they feel rested and revitalized following the infusion. We will continue to work closely with clinics to promote Niagen Plus as the superior experience and solution to boosting NAD levels. The pharmaceutical application of NR continues to be an important strategic initiative for the company. As it relates to the Phase III NOPARC study investigating the use of NR in the treatment of Parkinson's disease, we continue to be in consistent dialogue with the researchers and still expect that the study will be completed by June. Once the study is completed, we will not be able to see the results for a few months, but we look forward to sharing more updates as we know them. We continue to have ongoing dialogue with the FDA about NR for the treatment of ataxia telangiectasia, AT. We hope to have an update for you later this year. As for our intellectual property, we made a very important announcement in March that a new composition of matter patent was granted, broadening our patent portfolio and expanding protection for all salt forms of nicotinamide riboside. There is no form of NR that does not infringe upon one or two of the patents controlled by Niagen Bioscience. As most of you know, demand for products to boost NAD levels is surging. More consumers are understanding that Niagen is the trusted and most effective solution. While the NAD market continues to grow significantly, there continues to be a misconception that supplementing with NAD itself, either through oral supplementation or intravenous, is an effective way to elevate cell and tissue NAD levels. The proven fact is that NAD cannot bypass cell membranes and must be broken down into NAD precursors like NR to enter cells and increase NAD levels. NAD supplementation and IV continues to be mentioned in more press and on social media, despite not being an effective method to boost NAD levels. Furthermore, companies continue to take advantage of this trend and market pure NAD supplements on Amazon and other marketplaces. Taking NAD as a molecule in oral form does not elevate NAD. There are no studies to date that show that it does. you need a precursor. As the global leader in NAD science and commerce, we hold the responsibility to embody integrity and precision science to promote healthy aging. However, the same cannot be said for many of the other sellers of NAD supplements. Our ongoing market surveillance program shows that three quarters of the higher selling NAD supplements on Amazon fail to meet their label claims, three quarters. We continue to call upon like-minded industry stakeholders in holding companies and brands accountable by the products they market and sell to consumers. With regard to NMN, the FDA ruled that NMN is not a lawful dietary ingredient under the Federal Food, Drug, and Cosmetic Act. We recognize that the agency has been sued for this decision, but we reaffirm our position in support of the FDA and believe it will uphold this decision. As we continue to see NMN products find their way on the market, we urge the FDA to maintain and enforce its ruling to protect consumers and ensure that only compliant, properly regulated ingredients are marketed as dietary supplements. The fact is, if you're interested in an NAD product and that product does not say Niagen, I would recommend you stay away. As I mentioned before, this is the first call as Niogen Bioscience versus Chromadex. The evolution from Chromadex into Niogen Bioscience signifies more than just the company name. It is an alignment of our brand with our mission. Niogen Bioscience aims to reinforce Niogen at the forefront of NAD boosting solutions, making the name Niagen synonymous with healthy aging. We will continue to uphold these core values, scientific rigor, transparency, authenticity, innovation, and integrity. We are here to show you, our shareholders, our customers, and all our stakeholders, that thanks to Niagen, there is a better way to age. And I would now like to hand the call over to Ozan. to run through the quarter's financials, and then on to Q&A and closing remarks. Ozan.